Chad Moretz

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 4

Top Topics

Mesenchymal Stem Cells

Silver Nanoparticles

Chronic Obstructive Pulmonary Disease

Top Venues

International journal of chronic obstructive pulmonary disease

BMC pulmonary medicine

Pulmonary therapy

This page only lists publications with an associated author ORCID identifier.

Publications

David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Malena Mahendran, Beth Hahn
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study. BMC pulmonary medicine 21 (1) (2021)
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Qin Shen, Mei Sheng Duh, Sean D MacKnight, Beth Hahn
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary therapy 7 (1) (2021)
Morgan Justice Fuoco, Richard A Mularski, Benjamin Wu, Chad Moretz, Mary Ann McBurnie, Richard H Stanford, Phillip Crawford, Daniel Gratie, Bianca Salas
Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-Related Exacerbations. International journal of chronic obstructive pulmonary disease 16 (2021)
Chad Moretz, Beth Hahn, John White, Alyssa Goolsby Hunter, Breanna Essoi, Caitlin Elliott, Riju Ray
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. International journal of chronic obstructive pulmonary disease 15 (2020)